On the mechanism of tumor cell entry of aloe‐emodin, a natural compound endowed with anticancer activity
Open Access
- 14 May 2021
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 149 (5) , 1129-1136
Abstract
Aloe-emodin (1,8-dihydroxy-3-(hydroxymethyl)-anthraquinone), AE, is one of the active constituents of a number of plant species used in traditional medicine. We have previously identified, for the first time, AE as a new antitumor agent and shown that its selective in vitro and in vivo killing of neuroblastoma cells was promoted by a cell-specific drug uptake process. However, the molecular mechanism underlying the cell entry of AE has remained elusive as yet. In this report, we show that AE enters tumor cells via two of the five somatostatin receptors: SSTR2 and SSTR5. This observation was suggested by gene silencing, receptor competition, imaging and molecular modeling experiments. Furthermore, SSTR2 was expressed in all surgical neuroblastoma specimens we analyzed by immunohistochemistry. The above findings have strong implications for the clinical adoption of this natural anthraquinone molecule as an antitumor agent.Keywords
This publication has 24 references indexed in Scilit:
- Cell-type dependent response of melanoma cells to aloe emodinFood and Chemical Toxicology, 2012
- Anticancer Potential of Aloes: Antioxidant, Antiproliferative, and Immunostimulatory AttributesPlanta Medica, 2012
- Aloe emodin inhibits colon cancer cell migration/angiogenesis by downregulating MMP-2/9, RhoB and VEGF via reduced DNA binding activity of NF-κBEuropean Journal of Pharmaceutical Sciences, 2012
- Differentiated expression of somatostatin receptor subtypes in experimental models and clinical neuroblastomaPediatric Blood & Cancer, 2010
- Antitumor effects of somatostatinMolecular and Cellular Endocrinology, 2008
- The Renaissance of Natural Products as Drug CandidatesScience, 2005
- Opportunities in somatostatin research: biological, chemical and therapeutic aspectsNature Reviews Drug Discovery, 2003
- Involvement of p53 in specific anti‐neuroectodermal tumor activity of aloe‐emodinInternational Journal of Cancer, 2003
- Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. CohenJournal of Molecular Biology, 1997
- Voltage-dependent modulation of single N-Type Ca2+ channel kinetics by receptor agonists in IMR32 cellsBiophysical Journal, 1996